Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus

ClinicalTrials.gov ID

NCT06400537

Lead Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 1

Enrollment

25Estimated

Last Update Posted

Sep 17, 2025Actual

Start Date

Jul 20, 2024Actual

Primary Completion Date

Dec 2026Estimated

Completion Date

Dec 2026Estimated

Official Title

Clinical Study of Recombinant CD19xCD3 Double Antibody (A-319) in the Treatment of Active/Refractory Systemic Lupus Erythematosus

Brief Summary

The purpose of the study is to explore the safety and efficacy of recombinant CD19xCD3 double antibody (A-319) in active/refractory systemic lupus erythematosus (SLE).

Detailed Description

The pathogenic B cells of patients with SLE can produce a large amount of autoantibodies, which will form immune complexes and thereby inducing continuously expanding tissue damage and systemic inflammation. A-319 is a kind of recombinant CD19xCD3 double antibody, it can activate internal T cells to target and kill pathogenic B cells. Clinical trials of A-319 are currently underway in hematological maliganancies concerning B cell abnormality. Preclinical studies have shown the efficacy of A-319 in SLE. The aim of this study is to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and preliminary efficacy of A-319 in active/refractory SLE. Patients with active/refractory SLE will be invited to participate in the study, to receive A-319 intravenous infusion or subcutaneous injection and follow-up visits of up to 1 years after enrollment.

• Systemic Lupus Erythematosus

• A-319

Ages Eligible for Study

Adult (18-64)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Age 18-60 years old, regardless of gender;
2. Participants diagnosed with SLE according to the American College of Rheumatology (ACR) 1997 revised criteria for SLE at least 24 weeks prior to signing the informed consent form;
3. Active/refractory systemic lupus erythematosus;
4. Positive test results for at least one of the following autoantibodies at screening: antinuclear antibodies (ANA) immunofluorescence assay at a titer of ≥1:80; anti-dsDNA; or anti-Smith (anti-Sm);
5. Receive the standardized and stable treatment for at least 30 days before the first administration of the study drug;
6. Female participants tested negative for pregnancy, and participants agreed to use effective contraception throughout the trial;
7. Have the ability to understand the nature of the research and voluntarily sign an informed consent form;
8. Participants can communicate well with the researchers and complete all visits according to the requirements of the plan.

Exclusion Criteria:

1. Severe kidney disease;
2. Participants who have central nervous system diseases caused by SLE or non-SLE disease within 8 weeks before the first administration of the study drug;
3. Abnormities of main organ function at screening;
4. Medical history that the researchers believe will pose risk to the safety of the participants, or will affect the safety or effectiveness analysis of the study drug;
5. Active mycobacterium tuberculosis infection;
6. Active hepatitis, or hepatitis B virus surface antigen positive, or hepatitis B virus core antibody positive and hepatitis B virus deoxyribonucleic acid positive, ,or hepatitis C virus (HCV) antibody positive with detectable HCV ribonucleic acid (RNA).;
7. History of human immunodeficiency virus infection, or positive antibodies at screening;
8. Positive syphilis spirochete antibody at screening (except false positive caused by SLE);
9. Participants with chronic active infection or acute infection need systemic anti-infection treatment within 2 weeks before screening, or have superficial skin infection requiring treatment within 1 week before screening;
10. Have undergone major surgery or unhealed wounds, ulcers or fractures within 4 weeks before the first administration of the study drug, or plan to perform major surgery during the study period;
11. Participants diagonosed with malignant tumors within 5 years before screening;
12. History of important organ transplantation or hematopoietic stem cells/or bone marrow transplantation;
13. Have been vaccinated or plan to receive live vaccine or live attenuated vaccine during the research period within 4 weeks before the first administration of the study drug;
14. Participated in any clinical trial within 4 weeks before the first administration of the study drug or within 5 half-lives of the study drug of the clinical trial;
15. Received targeted drugs (rituximab, JAK inhibitors, etc.) at a specific time period before the first administration of the study drug;
16. Received intravenous immunoglobulin, prednisone ≥100mg/d or equivalent glucocorticoid therapy within 4 weeks before the first administration of the study drug, or plasma replacement;
17. Received IL-2, thalidomide, rethidone and traditional Chinese medicine within 4 weeks before the first administration of the study drug;
18. Known allergies to monoclonal antibody drugs, or allergies to A-319 excipients;
19. Participants with depression or suicidal thoughts;
20. Women who are pregnant or breastfeeding, or women who plan to be pregnant or breastfeeding during the study period; or men whose sexual partners plan to become pregnant during the study period;
21. Any reason that the researchers believe will hinder the subject's participation in the study.

Primary Purpose

Treatment

Allocation

Non-Randomized

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER

Collaborators

ITabMed Co., Ltd.INDUSTRY

1315710223@qq.com

• Clinical Study of (A-319) in the Treatment of Active Rheumatoid Arthritis

  NCT07347860

  RecruitingInterventionalEarly Phase 1Updated Jan 16, 2026
• Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma

  NCT04056975

  Unknown statusInterventionalPhase 1Updated Aug 14, 2019
• A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus

  NCT06106906

  RecruitingInterventionalPhase 1Phase 2Updated Jan 8, 2025
• A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus

  NCT07339332

  RecruitingInterventionalEarly Phase 1Updated Jan 14, 2026
• Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus

  NCT06222853

  Active, not recruitingInterventionalPhase 1Updated Feb 4, 2026
• Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus

  NCT06421701

  Unknown statusInterventionalPhase 1Updated May 25, 2025